3 recruiting, 2 not yet recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Imlunestrant: new trials by email Literature Review of Imlunestrant trials Research Report on Imlunestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer Imlunestrant + abemaciclib, (dd)EC*4-T*4 - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 189 | 2026-07-01 | 2026-02-18 |
| Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial Abemaciclib, Biospecimen Collection, Imlunestrant - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 42 | 2026-05-18 | 2026-08-20 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Imlunestrant, Goserelin, Tamoxifen 20 mg - Breast Neoplasms | Phase 2 | Recruiting | Eli Lilly and Company | 600 | 2026-05-13 | 2026-10-08 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
Breast Neoplasms (3) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Breast Diseases (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasms (1) · Neoplasms by Site (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Eli Lilly and Company (2) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1)
United States (3) · Belgium (2) · France (2) · Germany (2) · Ireland (2) · Italy (2) · China (1) · Japan (1) · Netherlands (1) · Spain (1) · Taiwan (1)
Marla Lipsyc-Sharf (1) · Panagiotis Konstantinopoulos, MD, PhD (1)
2023 (1), 2025 (1)